Dealing with immunogenicity of biologicals: assessment and clinical relevance.
about
Assessing the Immunogenicity of BiopharmaceuticalsImmunogenicity of mAbs in non-human primates during nonclinical safety assessmentAssessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resourceThe Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.Understanding differences between synthetic and natural antibodies can help improve antibody engineering.Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?Pharmacokinetics of recombinant bifunctional fusion proteins.Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.New and emerging therapies for the treatment of rheumatoid arthritis.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Therapeutic options for rheumatoid arthritis.Assessing response and loss of response to biological therapies in IBD.Immunogenicity of therapeutic proteins: the use of animal models.Focus on skin cancer association and progression under TNF antagonist therapy.Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.When is switching warranted among biologic therapies in rheumatoid arthritis?The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.Biologic fatigue in psoriasis.Antidrug antibodies in psoriasis: a systematic review.Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.Anti-TNF in rheumatoid arthritis: an overview.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Subcutaneous abatacept in rheumatoid arthritis: current update.The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.Biosimilar regulation in the EU.Biosimilar monoclonal antibodies: the scientific basis for extrapolation.The Clinical Pharmacology of Elotuzumab.Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range.
P2860
Q26751485-5C4BEBA9-B5F0-4819-BE76-BF89367FD3A3Q30390955-BF44087E-D37E-4420-B9E4-2232C2C1C238Q33804009-97AC596B-17F2-4BB5-A9E3-B30A52A47B26Q35039995-434C6E8C-9A73-4D31-B785-BD45B78D56ABQ35840998-36451629-1916-40BF-915B-0744784F6F1BQ35864868-5A68D160-240D-4E8B-AB9E-53EB63C328D2Q36485104-869C051A-90BD-4C1A-A4F9-09F0BEB1609BQ36575283-C19FF7AB-7894-4CB5-8CB1-0EB6D265B389Q37033032-D4F4E24A-1CB7-49F9-8C76-24C5E932CC6CQ37215981-9BD62683-C177-412D-9A7A-CFAAE12EC1CAQ37358229-0E4EF8AD-BA24-464E-936C-1E7BD3F0FE30Q37517101-B8A37324-00F7-48A6-85A5-04A13C416FD8Q37552947-2F5C01C9-87F7-4ED6-8190-9B92CD31CD63Q37856191-8BB9A3D2-5B36-4E99-AA92-8A124794F4C1Q37899800-E256BBD8-59EB-44C6-B8D4-60DA72376367Q37901473-5324EE21-F37C-4895-9CB7-AB7E355FF046Q37923355-622EC1C9-F4FF-4FBA-B51D-7AC1C62C1CA7Q38027571-0A9D92AF-3FF6-45DD-A296-67D42A1D547EQ38033127-19004F8C-88E7-47AD-AC2D-4E4ABDAD8669Q38033153-9160F8F1-3F3D-4FDA-9C0C-0A94C29FEE4AQ38045471-FD557D1E-7892-4E79-84E1-2B580731CA3EQ38063585-BC6FE84F-8FD3-423A-9511-D517FB9E00D5Q38095548-8FBB2A2F-73E3-4B18-8D6A-3BFA03837BF8Q38123192-A75F14B9-EFCF-4F74-AEEE-77F803609215Q38151757-A5CC0A2F-7370-4D8A-8131-4796F2E85599Q38152820-9FCCD8FA-C5C7-4DD5-ABAC-231E7A7385B1Q38212907-BA024540-02E3-46DA-9D83-1C29636C650EQ38222900-77ABB01A-B61F-4465-9BCC-9DC8A28F797CQ38344282-E9EF9321-7E21-4FC1-AC70-2ADB13819BABQ38537167-CD4B2BF5-9F30-4192-B8EB-76441C499B0FQ38544693-F7186454-6E48-4EF2-A121-21233B51B3E3Q38568813-327C4735-FCBF-4EF5-85F6-F5F5AE419851Q38570723-E8C4EF6B-4E4E-4FEF-B241-498102ACFD00Q38586044-967AD043-D516-4C7D-8784-13849D9DBE73Q38639376-8759B147-1117-4D17-A270-E1056987A1F3Q38643965-354FE3C9-6077-44CE-862C-F611A9E06A2DQ38822920-4A44D560-B43A-4017-B730-52BAEEC101D9Q38898145-709B5DCA-67AC-40A3-AE04-990A9F74B511Q39138759-BE06E9FA-994D-4C36-B952-37C7CB74224BQ40206740-C796BF1B-4974-40EF-BCAA-212CD0A8366A
P2860
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@en
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@nl
type
label
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@en
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@nl
prefLabel
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@en
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@nl
P2093
P1476
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
@en
P2093
B A C Dijkmans
Gerrit J Wolbink
Lucien A Aarden
P304
P356
10.1097/BOR.0B013E328329ED8B
P577
2009-05-01T00:00:00Z